More Stories

Informist, Friday, Sept. 26, 2025

MUMBAI – Nifty pharma index is likely to move in a range with a negative bias next week after US President Donald Trump announced a 100% tariff on the branded and patented pharmaceutical imports to the US, analsyts said. Despite marginal exposure to the branded segment in the US, negative sentiment will persist in the market due to confusion around the products that will come under the tariff slab. 

There is confusion around whether the proposed tariffs will include branded generics, a significant business for several Indian pharma companies. Analysts are waiting for the final executive order to gauge the impact on drug companies. Mehul Sheth, research analyst at HDFC Securities, said the language used in the executive order will be crucial in determining the impact on pharma companies.

The Trump administration's push for global pharma companies to set up manufacturing units in the US may not be feasible for Indian drug makers, an analyst at a domestic brokerage said. Talent shortages in the US and the presence of other global players in the branded products business make it difficult for Indian companies to build manufacturing plants in the US. Contract-based deals with US contract development and manufacturing organisations may be a viable alternative.

Analysts at domestic brokerages said the impact of the US tariffs on Indian pharma companies will depend on the specifics of the executive order and the products that come under the tariff slab. While some companies may face significant challenges, others may be relatively insulated. In the short term, pharma sector sentiment is likely to remain weak, with companies having higher exposure to the US market being considered riskier. Analysts are also watchful of the impact of tariffs on the active pharmaceutical ingredient segment, which is another crucial part of the overall industry.

For the week ended Friday, the Nifty Pharma closed over 5% lower at 21507.20. Technical analysts said that the index will find support around 20900 and find resistance around 21600 levels.  

TOP HEADLINES

* Pharmexcil head says tariffs not to hit India, generics a cost saving for US
* Glenmark Pharma board OKs interim dividend of INR 2.50 per share for FY26
* Trump to impose 100% tariff on branded, patented pharma pdts from Oct 1
* Alembic Pharma gets US FDA final OK for Paroxetine extended-release tablets
* HSBC Global ups rtg, target price of Nestle, Britannia on GST cut benefits
* Natco Pharma's board gives in-principle nod to evaluate demerger of agro ops
* Ipca Lab, BioSimilar Sciences in pact for tech transfer, joint development
* Pharma sector's revenue growth to moderate to 7-9% in FY26, says Crisil
* Lupin gets tentative approval from US FDA for generic of Biktarvy tablets
* Glenmark arm enters into pact with Hengrui Pharma for trastuzumab rezetecan
* Dabur gets tax demand, penalty of INR 2.71 bln each from central GST dept
* Torrent Pharma gets South Africa competition panel OK to buy stake in JB Chem
* Neuland Lab names Saharsh Rao as MD, CEO; Sucheth as executive vice-chairman
* HC OKs Patanjali to use ordinary chyawanprash in advt but remove Dabur link
* Jubilant Pharmova appoints Arun Kumar Sharma as interim CFO from Oct 1
*  IPO Alert: Medicap Healthcare files DRHP for INR 2.40 bln fresh issue
* Concord Biotech eyes domestic, other markets to mitigate US tariff threats
* Dr Reddy's gets Europe drug agency's positive view for denosumab biosimilar
* Glenmark Pharma board to mull interim dividend, revises record date to Oct 3
* Alkem Lab launches biosimilar Pertuza injection in India for breast cancer
* Glenmark Pharma board to meet Fri to mull interim dividend for FY26
* GST Rejig: Dabur India cuts product prices across multiple categories
* US FDA tags Zydus Life Ahmedabad oncology unit 'voluntary action indicated'
* US FDA ends inspection of Jubilant Pharmova US arm with no observations
* US FDA issues 4 observations to Lupin's Pune unit post pre-approval checks
* Indegene in pact with Datavant to recruit patients for clinical trials
* Dr Reddy's promoters GV Prasad, Satish Kallam transfer shrs to family trusts

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Akul Nishant Akhoury

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.